BiotechTube
Home/Enlila/Jane Smith
JS

Jane Smith

CSO

Enlila

Therapeutic Areas

MetabolismAgingObesityCardiovascular DiseaseDiabetes

Enlila Pipeline

DrugIndicationPhase
ENL‑101Obesity‑related inflammationPreclinical
ENL‑102Non‑alcoholic fatty liver diseasePreclinical
ENL‑103AtherosclerosisPreclinical

Leadership Team at Enlila

JD
John Doe
CEO
View full Enlila profile